HENDERSON MICHAEL THOMAS 4

What Happened Michael Thomas Henderson, CEO of Apogee Therapeutics (APGE), exercised stock options on April 16, 2026, acquiring 3,000 shares at an exercise price of $22.86 per share for a total cash outlay of $68,580. The Form 4 also reports a related derivative disposition of 3,000 units at $0.00; the filing lists this as an option exercise/conversion (transaction code M).

Key Details

• Transaction date: 2026-04-16.
• Acquisition: 3,000 shares acquired via option exercise at $22.86 each (total $68,580).
• Disposition: 3,000 derivative units reported disposed at $0.00 (listed as conversion/exercise).
• Shares owned after the transaction: not specified in the filing.
• Footnote: the underlying option grant covers the right to purchase 398,512 shares, vesting in 48 equal monthly installments over four years (see F1).
• Filing timeliness: Form filed 2026-04-20 for a 2026-04-16 transaction; no late filing flag indicated.

Context This was an option exercise (code M). The filing does not report any immediate open-market sale of the acquired shares (no cashless sale reported), so the Form 4 indicates acquisition rather than a sale. Footnote F1 shows the exercised options are part of a larger grant subject to time-based vesting. As always, insider option exercises are factual events and do not, by themselves, indicate the insider’s view of the company.